Orotic Acid

• Array
• Array

Primary Pathway: Orotic acid serves as a key intermediate in the de novo pyrimidine synthesis pathway, which is essential for the production of nucleotides required for DNA and RNA synthesis. In this pathway, orotic acid is produced from carbamoyl phosphate and aspartate through several enzymatic steps. The enzyme dihydroorotate dehydrogenase (DHODH) catalyzes the conversion of dihydroorotic acid to orotic acid. Subsequently, orotic acid is converted to orotidine monophosphate (OMP) by the enzyme orotate phosphoribosyltransferase, using phosphoribosyl pyrophosphate (PRPP) as a co-substrate. OMP is then decarboxylated to form uridine monophosphate (UMP) by OMP decarboxylase. UMP serves as a precursor for other pyrimidine nucleotides essential for nucleic acid synthesis.

Secondary Pathways: Beyond its role in pyrimidine synthesis, orotic acid participates in several other metabolic pathways. It influences liver metabolism, particularly pathways related to lipid processing. At high doses, orotic acid can affect lipid metabolism by inhibiting the secretion of very low-density lipoproteins (VLDL) from the liver, potentially leading to fatty liver in experimental models. Orotic acid may also influence carbohydrate metabolism through interactions with various metabolic enzymes. Additionally, when complexed with minerals as orotates, it may participate in mineral transport and utilization pathways, potentially enhancing mineral delivery to intracellular sites.

Regulatory Mechanisms: The synthesis and metabolism of orotic acid are regulated through multiple mechanisms. The rate-limiting step in the pyrimidine synthesis pathway is typically the conversion of carbamoyl phosphate and aspartate to N-carbamoylaspartate by aspartate transcarbamylase, which is subject to feedback inhibition by downstream pyrimidine nucleotides. This helps maintain appropriate levels of pathway intermediates, including orotic acid. Additionally, the activity of dihydroorotate dehydrogenase, which produces orotic acid, is influenced by cellular energy status and mitochondrial function. In certain metabolic disorders or enzyme deficiencies, orotic acid may accumulate, leading to orotic aciduria.

Receptor Binding: Unlike many bioactive compounds, orotic acid does not primarily exert its effects through direct binding to specific receptors. Instead, it functions as a metabolic intermediate and mineral carrier. However, some research suggests orotic acid may interact with certain nuclear receptors involved in lipid metabolism, potentially explaining some of its effects on hepatic lipid processing, though these interactions are not well-characterized.

Enzyme Interactions: Orotic acid interacts with several enzymes as a substrate or modulator. As a substrate, it is acted upon by orotate phosphoribosyltransferase in the pyrimidine synthesis pathway. It may also influence the activity of enzymes involved in lipid metabolism, including those responsible for triglyceride synthesis and VLDL assembly and secretion. When administered as mineral orotates, the compound may affect various enzyme systems depending on the specific mineral component, such as magnesium-dependent enzymes in the case of magnesium orotate.

Transporter Interactions: Orotic acid utilizes specific transporters for cellular uptake, including members of the solute carrier (SLC) family. These transporters facilitate the movement of orotic acid across cell membranes, allowing it to participate in intracellular metabolic processes. Additionally, mineral orotates may interact with various mineral transporters, potentially offering alternative transport mechanisms for the mineral components. The theory behind mineral orotates suggests they may bypass conventional mineral transport systems, allowing direct delivery to intracellular sites, though evidence for this mechanism varies by specific mineral.

Signaling Cascades: Orotic acid may influence various cellular signaling pathways, though these effects are not as well-characterized as its metabolic roles. In liver cells, it may affect signaling pathways related to lipid metabolism and transport, potentially through interactions with nuclear receptors or other signaling molecules. Mineral orotates may influence signaling cascades specific to their mineral components. For example, magnesium orotate may affect signaling pathways involved in energy metabolism, muscle contraction, and neuronal function through the actions of magnesium on various signaling molecules and ion channels.

Gene Expression: Orotic acid may influence gene expression patterns, particularly for genes involved in nucleic acid metabolism, lipid processing, and energy production. This influence likely occurs through both direct effects on nucleotide availability for transcription and potential indirect effects on transcription factors or other regulatory elements. Mineral orotates may additionally affect gene expression patterns specific to their mineral components, such as magnesium-responsive genes in the case of magnesium orotate.

Metabolic Effects: At the cellular level, orotic acid supports nucleic acid synthesis by providing essential pyrimidine precursors. It may also influence energy metabolism, particularly in tissues with high metabolic activity such as the liver, heart, and skeletal muscle. In liver cells, high concentrations of orotic acid can alter lipid metabolism, potentially leading to increased triglyceride synthesis and reduced VLDL secretion. Mineral orotates may provide additional metabolic effects through their mineral components, such as supporting ATP production and utilization in the case of magnesium orotate.

Cardiovascular System: In the cardiovascular system, orotic acid, particularly as magnesium orotate, may support heart function through several mechanisms. Magnesium is essential for proper cardiac electrophysiology, muscle contraction, and energy metabolism. The orotate component may enhance magnesium delivery to cardiac tissues and potentially provide additional benefits through support of nucleic acid metabolism and cellular energy processes. Some research suggests magnesium orotate may help protect cardiac tissue during stress or ischemia, support energy production in cardiac mitochondria, and help maintain normal cardiac rhythm and contractility.

Liver: The liver is a major site of orotic acid metabolism and a target for its effects. Orotic acid participates in hepatic pyrimidine synthesis and may influence various aspects of liver metabolism. At high doses, it can affect lipid metabolism in liver cells, potentially altering the balance between triglyceride synthesis and secretion. This effect has been studied extensively in animal models, where high-dose orotic acid has been used experimentally to induce fatty liver through inhibition of VLDL secretion. At more moderate doses, orotic acid may support normal liver function through its role in nucleic acid metabolism and potential effects on liver regeneration processes.

Nervous System: In the nervous system, orotic acid may support neuronal function through its role in nucleic acid metabolism and potential effects on energy production. Certain mineral orotates, particularly lithium orotate, have been studied for potential neurological and psychiatric applications. Lithium orotate is claimed to deliver lithium more efficiently to neural tissues compared to conventional lithium salts, potentially allowing for lower doses and reduced side effects, though evidence for superior brain delivery remains limited. The orotate component itself may support neuronal metabolism and potentially influence neurotransmitter systems, though these effects are not well-characterized.

Musculoskeletal System: In the musculoskeletal system, orotic acid, particularly as magnesium orotate, may support muscle function and energy metabolism. Magnesium is essential for muscle contraction, relaxation, and energy production. The orotate component may enhance magnesium delivery to muscle tissues and potentially provide additional benefits through support of nucleic acid metabolism and cellular energy processes. Some research suggests magnesium orotate may help support exercise performance and recovery, particularly during periods of increased physical stress or in conditions involving muscle weakness or fatigue.

Absorption: Orotic acid is absorbed from the gastrointestinal tract, primarily in the small intestine. Absorption appears to be moderately efficient, though not complete, with bioavailability estimated at approximately 40-60%. The absorption process likely involves both passive diffusion and active transport mechanisms utilizing specific transporters from the solute carrier (SLC) family. Mineral orotates may have different absorption characteristics depending on the specific mineral component. For example, magnesium orotate may offer improved magnesium absorption compared to some other magnesium forms, though comparative bioavailability studies show mixed results.

Distribution: Following absorption, orotic acid distributes throughout the body, with particular affinity for tissues with high metabolic activity including the liver, heart, and skeletal muscle. It can cross cell membranes through specific transporters and participate in intracellular metabolic processes. Mineral orotates are generally thought to remain intact during absorption and initial distribution, though this varies by specific mineral. The distribution pattern of mineral orotates may differ from conventional mineral forms, potentially offering targeted delivery to specific tissues, though evidence for this mechanism varies by specific mineral.

Metabolism: Orotic acid is primarily metabolized through the pyrimidine synthesis pathway, where it is converted to orotidine monophosphate (OMP) and subsequently to uridine monophosphate (UMP) and other pyrimidine nucleotides. This metabolic pathway occurs primarily in the liver but also in other tissues with high nucleic acid synthesis requirements. A portion of administered orotic acid may undergo direct excretion without metabolism. When administered as mineral orotates, the compound may dissociate, with the mineral component following its typical metabolic pathways and the orotic acid component entering the pyrimidine synthesis pathway or undergoing excretion.

Elimination: Orotic acid and its metabolites are primarily eliminated through renal excretion. Unmetabolized orotic acid and various metabolites appear in the urine, with elimination half-life estimated at several hours. A small portion may undergo biliary excretion and elimination through feces. Mineral components of orotate compounds follow their typical elimination pathways once dissociated from the orotic acid. The relatively straightforward elimination profile contributes to the generally favorable safety profile of orotic acid at typical supplemental doses.

Onset Of Action: The onset of action for orotic acid varies depending on the specific application and form used. For basic metabolic effects related to pyrimidine synthesis, onset may begin within hours of administration as the compound is absorbed and enters metabolic pathways. For mineral orotates, the onset of effects related to the mineral component may follow similar timeframes to other mineral supplements, typically beginning within hours to days. For specific therapeutic applications such as cardiovascular support with magnesium orotate, noticeable effects may take days to weeks of regular supplementation to develop fully.

Peak Effects: Peak plasma levels of orotic acid typically occur within 1-3 hours after oral administration, depending on dosage form and individual factors. However, peak physiological effects may follow different timeframes depending on the specific mechanism and target tissue. For mineral orotates, peak effects related to addressing mineral deficiencies may take days to weeks of regular supplementation. For applications like cardiovascular support with magnesium orotate, peak benefits may require several weeks of consistent use to develop fully as tissues reach optimal mineral status and adapt metabolically.

Duration Of Action: The duration of action for a single dose of orotic acid is relatively short, typically several hours, corresponding to its elimination half-life. However, with regular supplementation, more sustained effects may develop as the compound influences ongoing metabolic processes and, in the case of mineral orotates, as mineral status improves in target tissues. For therapeutic applications requiring sustained effects, regular daily dosing is typically recommended, often divided into multiple doses to maintain more consistent blood levels throughout the day.

Development Of Tolerance: Limited evidence exists regarding the development of tolerance to orotic acid or mineral orotates with long-term use. For basic metabolic functions, significant tolerance would not be expected as the compound serves as a metabolic intermediate rather than a receptor agonist or antagonist. For mineral orotates, the effects would primarily relate to addressing mineral status, with diminishing returns possible once optimal status is achieved rather than true pharmacological tolerance. Some practitioners recommend periodic breaks from supplementation for long-term use, though this approach is based more on general supplement principles than specific evidence of tolerance development.

Physiological Factors: Several physiological factors may influence the efficacy of orotic acid and mineral orotates. Baseline nutritional status, particularly existing mineral levels for mineral orotates, can significantly affect response, with greater benefits typically seen in those with suboptimal status. Liver function may affect orotic acid metabolism and its effects on pyrimidine synthesis and lipid metabolism. Kidney function influences elimination of orotic acid and mineral components, potentially affecting both efficacy and safety with impaired function. Age-related changes in metabolism, absorption, and tissue responsiveness may also influence efficacy, with potential differences in response between younger and older individuals.

Pathological Conditions: Various pathological conditions may influence the efficacy and appropriate use of orotic acid and mineral orotates. Liver disorders may alter orotic acid metabolism and potentially increase sensitivity to its effects on lipid metabolism. Kidney dysfunction may affect elimination and potentially increase risk of accumulation with higher doses. Certain metabolic disorders, particularly those affecting pyrimidine metabolism such as hereditary orotic aciduria, represent special cases where orotic acid supplementation may be contraindicated or require specialized management. For mineral orotates, conditions affecting mineral homeostasis or transport may influence response and appropriate dosing.

Drug Interactions: Several types of drug interactions may influence the efficacy of orotic acid and mineral orotates. Medications affecting pyrimidine metabolism or nucleic acid synthesis may interact with orotic acid’s metabolic roles. For mineral orotates, interactions may occur with medications affected by the specific mineral component, such as certain antibiotics or blood pressure medications with magnesium orotate. Additionally, medications that significantly affect liver or kidney function may indirectly influence orotic acid metabolism and elimination, potentially affecting both efficacy and safety profiles.

Genetic Variations: Genetic factors may influence individual response to orotic acid and mineral orotates. Polymorphisms in genes encoding enzymes involved in pyrimidine metabolism, such as dihydroorotate dehydrogenase or orotate phosphoribosyltransferase, could affect how efficiently supplemental orotic acid is utilized. Genetic variations affecting mineral transport and metabolism may influence response to mineral orotates. Additionally, genetic factors affecting liver metabolism or kidney function could indirectly influence orotic acid processing and elimination, potentially creating individual differences in both efficacy and side effect profiles.

Vs Similar Compounds: Compared to other pyrimidine precursors or intermediates such as uridine, orotic acid occupies an earlier position in the pyrimidine synthesis pathway. While uridine can directly enter the salvage pathway for pyrimidine nucleotide synthesis, orotic acid must first be converted to orotidine monophosphate and then to uridine monophosphate. This difference may influence their relative effects on nucleic acid metabolism and other cellular processes. Compared to other mineral carriers or chelating agents, orotates are claimed to offer enhanced mineral delivery to intracellular sites, though evidence for superior bioavailability varies by specific mineral and comparative form.

Vs Conventional Therapies: For cardiovascular applications, magnesium orotate may offer certain advantages over conventional magnesium supplements through potentially enhanced delivery to cardiac tissues and the additional metabolic support provided by the orotate component, though comparative clinical evidence is limited. For liver support, orotic acid’s role in pyrimidine metabolism offers a different mechanism than conventional hepatoprotective agents that typically focus on antioxidant protection or bile flow enhancement. For mineral supplementation generally, orotates represent an alternative to conventional mineral forms such as oxides, citrates, or amino acid chelates, with potential differences in absorption, tissue distribution, and cellular effects.

Synergistic Compounds: Several compounds may act synergistically with orotic acid or mineral orotates. B vitamins, particularly those involved in one-carbon metabolism such as folate, vitamin B12, and vitamin B6, may complement orotic acid’s role in nucleic acid metabolism. Antioxidants may provide complementary protection during periods of increased metabolic activity supported by orotic acid. For mineral orotates, other nutrients involved in the specific mineral’s metabolism or function may offer synergistic effects. For example, with magnesium orotate, vitamin B6 may enhance magnesium utilization, while taurine may complement its cardiovascular effects.

Antagonistic Compounds: Certain compounds may potentially antagonize or interfere with the actions of orotic acid or mineral orotates. Substances that significantly alter liver metabolism might affect orotic acid processing and its effects on pyrimidine synthesis. For mineral orotates, compounds that compete for absorption or interfere with mineral utilization could potentially reduce efficacy. For example, high doses of zinc might interfere with magnesium absorption from magnesium orotate. Additionally, medications that affect kidney function might influence the elimination of orotic acid and mineral components, potentially affecting both efficacy and safety profiles.

Overall Safety Rating: Generally Recognized as Safe (GRAS) at recommended doses

Safety Context: Orotic acid has a generally favorable safety profile at typical supplemental doses. As an endogenously produced compound involved in normal pyrimidine metabolism, moderate supplementation appears well-tolerated by most individuals. However, safety considerations change significantly at higher doses, particularly regarding potential effects on liver metabolism. The safety profile also varies depending on the specific mineral form (orotate) being used, as the mineral component contributes its own safety considerations.

Regulatory Status:

• Not approved for treatment of any medical condition in the US. Regulated as a dietary supplement ingredient under DSHEA. Mineral orotates are similarly regulated as dietary supplements.
• No specific opinions issued regarding orotic acid as a supplement ingredient. Mineral orotates are available as food supplements in many European countries.
• Permitted as a dietary supplement ingredient. Some mineral orotates are recognized as Natural Health Products (NHPs).
• Available as a complementary medicine ingredient. Some mineral orotates are listed in the Australian Register of Therapeutic Goods (ARTG).

Population Differences: Safety may vary across different populations. Individuals with liver dysfunction may be more susceptible to adverse effects, particularly at higher doses. Those with kidney impairment may have altered clearance of orotic acid and mineral orotates. Elderly individuals may have different responses due to age-related changes in metabolism and elimination. Limited data exists on safety in pregnant or breastfeeding women, warranting caution in these populations.

Common Side Effects:

Rare Side Effects:

Theoretical Concerns:

Absolute Contraindications:

Relative Contraindications:

Special Populations:

Significant Interactions:

Moderate Interactions:

Minor Interactions:

Common Allergens:

• True allergic reactions to orotic acid appear to be rare. As a compound naturally present in the body and various foods, it typically has low allergenic potential. However, as with any substance, individual hypersensitivity can occur.
• No well-established patterns of cross-reactivity exist. Theoretical potential for individuals with sensitivities to other pyrimidine derivatives or structurally related compounds, though this appears to be uncommon in practice.
• Allergic or sensitivity reactions to orotic acid supplements may more commonly relate to additional ingredients in the formulation rather than orotic acid itself. These might include fillers, binders, coating materials, or other excipients used in tablet or capsule production.

Allergic Reaction Characteristics:

• If allergic reactions occur, they may manifest as skin rashes, itching, hives, digestive disturbances, or respiratory symptoms in more severe cases. Anaphylactic reactions would be extremely rare but theoretically possible as with any substance.
• Typical allergic reactions would be expected to occur within minutes to hours after consumption, though delayed hypersensitivity reactions could potentially develop over days with repeated exposure.
• No specific risk factors for orotic acid allergy have been well-established. General risk factors for supplement allergies include history of multiple allergies, autoimmune conditions, or previous adverse reactions to supplements.

Hypoallergenic Formulations:

• No specific hypoallergenic formulations of orotic acid are widely marketed as such. For sensitive individuals, pure orotic acid powder or simple formulations with minimal additional ingredients may be preferable to complex formulations with multiple excipients.
• Those with known sensitivities should look for products free from common allergens such as gluten, dairy, soy, or artificial colors and preservatives. Capsules may be preferable to tablets for some sensitive individuals as they typically contain fewer binders and fillers.
• Higher-grade products with greater purity and fewer additives may reduce the risk of reactions in sensitive individuals. Pharmaceutical-grade orotic acid or mineral orotates typically have higher purity standards than general supplement grades.

Acute Toxicity:

• Animal studies indicate relatively low acute toxicity. Oral LD50 in rats has been reported as greater than 5000 mg/kg body weight, suggesting low acute toxicity potential at typical supplemental doses in humans.
• Not firmly established in humans. Clinical studies have used doses up to 3000 mg daily of magnesium orotate (providing approximately 1500-2000 mg orotic acid) without serious acute adverse effects. Higher doses may increase risk of gastrointestinal side effects and potential metabolic effects.
• Specific overdose symptoms are not well-characterized in humans. Based on animal studies and known effects, potential symptoms might include gastrointestinal disturbances, headache, dizziness, and potentially liver stress with very high acute doses. Mineral orotates may additionally cause symptoms related to mineral excess.

Chronic Toxicity:

• Limited long-term human studies exist. Animal studies suggest potential for fatty liver development with prolonged high-dose exposure (1% or more of diet), though this effect appears to be dose-dependent and influenced by other dietary factors. Clinical studies using moderate doses (e.g., 3000 mg magnesium orotate daily) for periods up to one year have not reported significant chronic toxicity issues.
• Liver appears to be the primary target organ for potential toxicity, particularly at higher doses. For mineral orotates, additional considerations relate to the specific mineral component (e.g., kidney considerations for magnesium or lithium orotates).
• Limited data available. Standard carcinogenicity studies meeting current regulatory standards are lacking. Available evidence does not suggest carcinogenic potential at typical supplemental doses, but comprehensive evaluation is incomplete.
• Limited data available. Standard mutagenicity studies meeting current regulatory standards are lacking. Available evidence does not suggest significant mutagenic potential at typical supplemental doses, but comprehensive evaluation is incomplete.

Reproductive Toxicity:

• Limited data available on potential effects on fertility. Animal studies have not identified significant concerns at moderate doses, but comprehensive evaluation is lacking.
• Limited data available on potential developmental effects. As a precautionary measure, orotic acid supplementation is generally not recommended during pregnancy unless specifically indicated and supervised by healthcare providers.
• Limited data available on safety during lactation. Orotic acid is naturally present in milk, but supplemental doses may result in different concentrations. As a precautionary measure, high-dose supplementation is generally not recommended during lactation unless specifically indicated.

Genotoxicity:

• Limited data available. Standard genotoxicity studies meeting current regulatory standards are lacking. As a natural component of nucleic acid metabolism, significant genotoxicity would not be expected at physiological or moderate supplemental doses, but comprehensive evaluation is incomplete.
• Limited data available. Standard chromosomal aberration studies meeting current regulatory standards are lacking. Available evidence does not suggest significant concerns at typical supplemental doses, but comprehensive evaluation is incomplete.
• Limited data available. Potential epigenetic effects have not been well-studied, though as a compound involved in nucleic acid metabolism, theoretical potential exists for effects on methylation or other epigenetic processes at higher doses.

Common Contaminants:

• Standard concerns for oral supplements apply, including potential for microbial contamination if good manufacturing practices are not followed. No specific biological contamination issues unique to orotic acid have been identified.
• Potential for heavy metal contamination exists as with any supplement, particularly for mineral orotates where the mineral source may introduce contaminants if not properly purified. Residual solvents from extraction or synthesis processes are another potential concern.
• Depending on manufacturing methods, residual chemicals from synthesis or purification processes could potentially be present. These might include solvents, catalysts, or reagents used in production.

Quality Indicators:

• Pure orotic acid typically appears as a white to off-white crystalline powder. Discoloration may indicate impurities or degradation. Mineral orotates may have slightly different appearances depending on the specific mineral and formulation.
• Orotic acid has limited solubility in water (approximately 0.5 g/L at 25°C) and is more soluble in hot water. Mineral orotates have varying solubility profiles depending on the specific mineral. Deviations from expected solubility may indicate quality issues.
• High-performance liquid chromatography (HPLC) is commonly used to assess purity and identity. For mineral orotates, additional testing for mineral content and identity is important. Nuclear magnetic resonance (NMR) spectroscopy can provide detailed structural confirmation for higher-grade products.

Adulteration Concerns:

• Relatively low risk of intentional adulteration for pure orotic acid due to its moderate cost and specific applications. For mineral orotates, potential exists for misrepresentation of mineral content or use of lower-quality mineral sources.
• HPLC, mass spectrometry, and NMR can effectively identify orotic acid and assess purity. For mineral orotates, additional techniques such as atomic absorption spectroscopy or inductively coupled plasma mass spectrometry (ICP-MS) are important for verifying mineral content.
• No specific certification standards exist exclusively for orotic acid products. General supplement quality certifications such as USP (United States Pharmacopeia), NSF International, or third-party testing programs provide some quality assurance.

Recommended Monitoring:

• For typical supplemental doses (100-500 mg daily), routine monitoring is generally not necessary beyond attention to potential side effects. For higher doses or longer-term use, periodic assessment of liver function may be prudent.
• Those with liver conditions, kidney dysfunction, or taking multiple medications should consider more careful monitoring. This might include liver function tests, relevant mineral levels (for mineral orotates), and attention to potential drug interactions.
• Depending on specific concerns and dose: liver function tests (ALT, AST, bilirubin), lipid profile (particularly with higher doses), relevant mineral levels (for mineral orotates), and uric acid levels (for those with gout or history of uric acid stones).

Warning Signs:

• Persistent gastrointestinal discomfort, unusual fatigue, changes in urine color, or right upper quadrant discomfort might indicate potential liver effects and warrant evaluation, particularly with higher doses.
• Jaundice, severe abdominal pain, significant changes in liver function tests, or signs of allergic reaction (rash, itching, swelling, severe dizziness, difficulty breathing) would warrant immediate discontinuation and medical evaluation.
• For general supplementation at moderate doses, specific monitoring schedules are not typically necessary. For therapeutic applications using higher doses, baseline assessment followed by monitoring at 1-3 month intervals initially, then less frequently if stable, would be reasonable.

Long Term Safety:

• Limited data exists on very long-term use (multiple years). Theoretical concerns include potential effects on liver metabolism with higher doses and potential for mineral imbalances with long-term use of mineral orotates.
• No specific biomarkers for chronic orotic acid exposure have been established. Standard health parameters including liver function, lipid profiles, and relevant mineral levels (for mineral orotates) provide indirect monitoring options.
• No specific post-exposure monitoring protocols have been established. For those discontinuing after long-term, high-dose use, a follow-up assessment of liver function and relevant parameters based on the specific orotate compound used would be reasonable.